EcoDrugPlus

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSKMAG00000001029
Gene Symbol: LOC108232910
3 Cross references
206 Possible Orthologues:

Uncharacterized Loc108236096

Ensembl ID : ENSKMAG00000016560
Gene Symbol: LOC108236096
2 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSKMAG00000001872
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSKMAG00000009723
Gene Symbol: UTRN
3 Cross references
270 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSKMAG00000014929
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSKMAG00000006886
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSKMAG00000001085
Gene Symbol: LOC108239853
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSKMAG00000016095
Gene Symbol: VKORC1
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSKMAG00000015003
Gene Symbol: LOC108235074
3 Cross references
213 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSKMAG00000003311
Gene Symbol: LOC108247381
3 Cross references
211 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1f-Like

Ensembl ID : ENSKMAG00000003506
Gene Symbol: LOC108228711
3 Cross references
177 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSKMAG00000011986
Gene Symbol: LOC108232107
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).